Fernando B.
- Country
- France
- Department
- Oncologie
Research Overview
- TAILORswitch (PADA-2): ctDNA‑guided switch to camizestrant plus abemaciclib in ER‑positive HER2‑negative metastatic breast cancer
- Evaluation of Reduced Duration of Adjuvant Endocrine Therapy with Exemestane, Anastrozole, and Letrozole in Postmenopausal Women with Low-Risk HR+ HER2- Breast Cancer
- Phase III Non-Inferiority Trial of Ribociclib and Endocrine Therapy Versus Chemotherapy Plus Ribociclib in HR+ HER2- Intermediate-Risk Early Breast Cancer
Data & Insights
Has run more than one trial at 37 of 159 partner sites.
Specializations
Breast Cancer and Hormone Receptor-Positive Disease
The investigator is involved in clinical research on advanced breast cancer, with a strong focus on ER-positive, HER2-negative, and triple-negative breast cancer. This includes interest in early breast cancer, locally advanced disease, metastatic settings, and HER2-positive or HER2-low subtypes.
- Endocrine therapy and CDK4/6 inhibitor-based treatment
- PIK3CA, ESR1, and BRCA-guided strategies
- Neoadjuvant, adjuvant, and maintenance approaches
- Circulating tumour DNA-driven surveillance
Research interest also extends to metastatic breast cancer with central nervous system involvement and treatment-resistant disease.
Genitourinary Oncology
Clinical activity includes a broad range of prostate cancer and urothelial carcinoma studies, with attention to both metastatic and high-risk localized disease. The investigator is also engaged in research on renal cell carcinoma and other urinary tract malignancies.
- Metastatic castration-resistant prostate cancer
- PSMA-targeted therapy and radioligand approaches
- Muscle-invasive bladder cancer and urothelial carcinoma
- Clear cell and non-clear cell renal cell carcinoma
Interest also covers castration-sensitive prostate cancer, oligometastatic prostate cancer, and maintenance therapy in advanced urinary cancers.
Thoracic, Head and Neck, and Gastrointestinal Cancers
The investigator participates in trials across non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, and hepatocellular carcinoma. The portfolio also includes biliary tract cancer and pancreatic ductal adenocarcinoma.
- Advanced NSCLC and metastatic lung cancer
- Head and neck squamous cell carcinoma
- Colorectal, gastric, and pancreatic cancers
- Biliary tract and liver cancer
Research activity also includes biomarker-selected solid tumors and treatment strategies for locally advanced or recurrent metastatic disease.
Gynecologic and Rare Solid Tumors
Clinical research involvement spans endometrial cancer, ovarian cancer, cervical cancer, vulvar cancer, and uterine sarcoma, with additional interest in soft tissue sarcoma, mesothelioma, melanoma, and neuroendocrine tumors. The investigator is also active in studies of molecularly selected solid tumors.
- Advanced ovarian and endometrial malignancies
- Cervical and vulvar squamous cell carcinoma
- Soft tissue sarcoma and rare tumor settings
- FGFR-altered and TP53-mutated solid tumors
These activities reflect a therapeutic focus on difficult-to-treat cancers requiring precision oncology and targeted treatment selection.
Central Nervous System and Supportive Care
The investigator is also involved in trials addressing glioblastoma, diffuse midline glioma, and brain metastases, alongside selected studies in migraine with aura, multiple sclerosis, sepsis, and ventilator-associated pneumonia.
- Glioblastoma and diffuse midline glioma
- Brain metastasis in breast cancer
- Migraine aura prophylaxis
- Intensive care and infectious complications
Research interest also includes acute respiratory failure and other high-acuity conditions requiring therapeutic innovation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.